CClinicalTrials.gg
CompletedNCT02648984Updated May 5, 2017

Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With Closed Ventricular Septal Defect

An interventional study of The intervention is performing an exercise test in Pulmonary Vascular Disease, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Sex
All
01

Study summary

Pulmonary arterial hypertension (PAH) in patients with congenital heart disease usually develops secondary to chronic volume overload of the pulmonary circulation following left to right shunt. This overload leads to elevated pulmonary artery pressure (PAP) and later to increased pulmonary vascular resistance (PVR), leading to right ventricular dysfunction, considerable morbidity and even mortality.

Since PAH nowadays is mostly detected when symptoms occur and PAP are elevated, the disease already evolved to an advanced stage and treatment is often initiated too late. Our research group standardized the technique for the detection of early pulmonary vascular disease by bicycle stress echocardiography. The investigators now aim to assess this exercise technique in a group of patients with ventricular septal defect.

Read the detailed description

Pulmonary arterial hypertension (PAH) in patients with congenital heart disease usually develops secondary to chronic volume overload of the pulmonary circulation following left to right shunt. This overload leads to elevated pulmonary artery pressure (PAP) and later to increased pulmonary vascular resistance (PVR). PAH may lead to right ventricular and right atrial dysfunction, which may implicate considerable morbidity and even mortality.

Since PAH nowadays is mostly detected when symptoms occur and PAP are elevated, the disease already evolved to an advanced stage and treatment is often initiated too late. Our research group standardized the technique for the detection of early pulmonary vascular disease by bicycle stress echocardiography. Exercise-induced pulmonary hypertension has been recognised as a clinical entity, but is not included in the current guidelines on pulmonary hypertension. Further research in this area might imply the need for revision of the current PAH detection and treatment strategy.

By performing stress echocardiography and cardiopulmonary exercise testing, the investigators want to reach the following objectives:

  • To answer the question whether the abnormal increase in PAP during exercise, seen in patients with late atrial septal defect (ASD) type secundum closure, is also present in congenital heart disease (CHD) patients who were treated for other shunt lesions.
  • To apply this early detection technique in a broader population of CHD patients and to better define the predictive value of an elevated PVR during exercise.
02

Conditions studied

  • Pulmonary Vascular Disease

Keywords

  • Pulmonary vascular disease
03

In context

Vascular Diseases

1,027 studies on the registry are indexed under Vascular Diseases; 167 are open to participants now.

This study's enrollment of 45 is below the median of 78 across 639 interventional studies indexed under Vascular Diseases.

Browse Vascular Diseases studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Male or female subjects with ventricular septal defect (VSD) repair at least 6 months before study enrolment
  • No discrimination in type of VSD repair will be made (percutaneous or surgical)
  • Subjects must be able to perform exercise testing

Exclusion Criteria:

  • Other congenital heart disease
  • PAH of any aetiology other than VSD
  • Inclusion in other treatment protocols
  • Impairment of organic function (renal, hepatic)
  • Arterial hypotension (systolic blood pressure \< 85 mmHg)
  • Anaemia (Hb \< 10 g/dl)
  • Thrombocytopenia (\< 50000/µl)
  • Significant valvular disease, other than tricuspid or pulmonary regurgitation
  • Chronic lung disease or total lung capacity \< 80% of predicted value
  • History of pulmonary embolism
  • Cyanotic patients, patients in an unstable condition and patients who have to undergo re-intervention during the study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Other
    Patient group

    Patients with ventricular septal defect

    Other: The intervention is performing an exercise test

  • Other
    Control group

    Healthy control subjects

    Other: The intervention is performing an exercise test

Interventions

  • OtherThe intervention is performing an exercise test

    Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test

06

What researchers measure

Primary outcomes

  1. Pulmonary artery pressure - flow plot

    Time frame: Through study completion, an average of 1,5 years for the first testing, an additional 1 year for the retesting

Secondary outcomes

  1. Maximal Oxygen Uptake

    Time frame: Through study completion, an average of 1,5 years for the first testing, an additional 1 year for the retesting

07

Study locations

1 site
  • University Hospitals Leuven
    Leuven, 3000, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02648984
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Responsible party
prof. dr. Werner Budts (Werner Budts, MD, PhD, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Jan 7, 2016
Start date
Sep 2014
Primary completion
Jan 2017
Completion
Jan 2017
Last update
May 5, 2017

Study contacts

Werner Budts, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion